The Effect Of Milrinone On Chronic Heart Failure And Its Influence To Brain Natriuretic Peptide

Obejective：To investigate the efficacy and safety of the Milrinone inpatients with chronic heart failure and its influence to the plasma level of brainnatriuretic peptide. To provide feasible treatment strategies for clinicians and providethe scientific basis for evidence-based medicine for clinical drug therapy.Methods：60cases of cardiac function in III-IV grade (NYHA grade) inpatients with chronic heart failure from2011.3-2013.12in our hospital, digitalis andnitrates herein are poor in all subjects and after treatment for the study,; in tomilrinone injection of saline prior to50ug/kg20ml diluted amount of5to10minutesafter injection finish this basis; then per-minute0.5ug/kg250ml10%of the amountof glucose in the static point, l per minute ml infusion speed, continuous4h,continuous7d. Observed in patients before treatment and after4weeks of clinicalefficacy, ventricular systolic and diastolic function, affecting6-minute walkdistance, dyspnea, and other clinical manifestations of the score and plasma brainnatriuretic peptide levels, statistical analysis performed using spss17.0statisticalanalysis.Results: After4weeks of treatment, patients were observed treatmenteffect was found after treatment was significantly higher effective rate70.00%36.67%hardness before treatment, the treatment group was ineffective33.33%5.00%was significantly lower than before treatment, there were significantdifferences the statistical significance (p <0.01); patients after treatment6h,12h,24hsignificant improvements in dyspnea and other pre-clinical performance assessmentthan treatment, the difference was statistically significant (p <0.05), SV patients aftertreatment LVEF was significantly higher than before and treatment, LVEDV andLVESV significantly lower than before treatment, the differences were statisticallysignificant (p <0.05), after treatment, one week, two weeks and four weeks oftreatment group was significantly higher than the6-minute walk distance beforetreatment, but there was significant difference in plasma of statistical significance (p <0.05), while plasma brain natriuretic peptide levels were significantly lower thanbefore treatment, a significant difference was statistically significant (p <0.05),60patients died during treatment2(3.33%) cases of death due to heart failure,readmission7(11.662%) patients; adverse reactions was6(10.00%).Conclusions:(1) Milrinone can significantly improve dyspnea andclinical symptoms, reduce LVEDV and LVESV, with increasing LVEF and FS inpatients with chronic heart failure;(2) Based on the standard anti heart failuretreatment on the use of Milrinone can further improve the clinical treatment effect, inpatients with chronic heart failure, without increasing adverse reaction, high security.(3) Milrinone can significantly reduce chronic brain natriuretic peptide levels inpatients with heart failure.